Mr. Anderson brings over 30 years of senior executive leadership experience in the medical device industry. Mr. Anderson is the founder and Chairman of Revival Healthcare Capital, a sustainable, high impact investment firm that specializes in medical devices and diagnostics. He currently serves on the boards of Apollo Endosurgery (Nasdaq: APEN) and Cardiologs, a leading cardiovascular artificial intelligence company; on the Executive Advisory Board of LEK Consulting, a leading healthcare consulting firm; and as an Independent Director of ConvaTec Group Plc, a FTSE 250 company specializing in medical products and related technologies. Anderson previously served as Chairman of the Board and CEO of ConvaTec Group Plc, where in his one-year interim roles he created additional shareholder value through his “Pivot to Growth” strategy and new $150 million transformation plan. Prior to his time with Revival Healthcare Capital, Mr. Anderson served as the Managing Director of PTV Healthcare Capital. He also served as the Company Group Chairman of Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Anderson was a key architect behind the launch of the world’s first drug-eluting stent, the CYPHER®️ Sirolimus-eluting Coronary Stent. Anderson holds a B.B.A. in Marketing from Mississippi State University.
Mr. Ballinger is the Chief Executive Officer of Aldevron. He brings decades of experience in the medical device industry. Prior to joining Aldevron, he spent 25 years at Boston Scientific, a company focused on a variety of interventional medical specialties. During his last nine years at Boston Scientific, he served as Executive Vice President and Global President of the Interventional Cardiology division. Mr. Ballinger is a member of the Board of Directors of Silk Road Medical. Mr. Ballinger earned his BS in Mechanical Engineering from Michigan Technological University, and his MBA from the University of Minnesota’s Carlson School of Management.
Tanisha Carino, Ph.D., is a health policy expert bringing over 20 years of experience driving growth and impact across multiple healthcare leadership positions in the government, private, and non-profit sectors. She most recently served as Executive Vice President, Chief Corporate Affairs Officer of Alexion, a Fortune 500 biotechnology company focused on rare disease, which was recently acquired by AstraZeneca. Prior to Alexion, she served as Executive Director of FasterCures, a Center of the Milken Institute, a nonpartisan think tank whose mission is working with global government, philanthropic, and business leaders to accelerate treatments to patients. Previously, Dr. Carino was an executive at GlaxoSmithKline where she led the United States policy function. She also spent over ten years with Avalere Health, a premiere strategic advisory services and business intelligence firm, and worked in the U.S. Medicare program to improve access for its beneficiaries and support the development of real-world evidence in the establishment of national coverage determinations. Dr. Carino is a Fulbright Fellow and earned her Ph.D. in health policy from Johns Hopkins University. She is associate faculty at the Johns Hopkins Bloomberg School of Public Health, and she serves on the Board of Directors of the National Health Council, the Governing Board of the Patient-Centered Outcomes Research Institute (PCORI), and the Board of Directors of Alliance for Health Policy.
Dr. Chou is a general partner at The Vertical Group, a healthcare focused venture capital firm. He co-founded Silk Road with Michi Garrison in 2007 and served as initial CEO. His career includes practicing as an interventional cardiologist and experience as a medical device industry executive. He previously had general management and business development responsibilities in the Abbott Vascular Division of Abbott Laboratories and last served as Division Vice President and General Manager of the vascular closure managing the FDA approval and global launch of the Perclose and Starclose products. Prior to joining Abbott, Dr. Chou was the Director of the Adult Cardiac Catheterization Laboratory at the University of California, San Francisco where he remains Associate Professor of Medicine. Dr. Chou received an MD from Case Western Reserve University and a BS in Physics and Electrical Engineering from Carnegie Mellon University.
Mr. Lasersohn has thirty years of experience in health care venture capital investments. Prior to joining The Vertical Group’s predecessor, F. Eberstadt in 1981 as a member of its venture capital division, Mr. Lasersohn was a corporate attorney with Cravath, Swaine & Moore. Mr. Lasersohn has served on the boards of over thirty medical companies and currently serves on the Boards of Directors of Anova, Masimo Corporation, Oncomed, and Silk Road Medical. He previously served on the boards of Bacchus Vascular, CardioThoracic Systems, Inc., Cardiovascular Imaging Systems, Inc., E.P. Technologies, Integrated Vascular Systems, Kyphon Inc, Metabolix and Proteolix . Mr. Lasersohn served on the Executive Committee of the Board of Directors of the National Venture Capital Association and is a past Chairman of the Medical Industry Group of the NVCA . He was the recipient of the NVCA’s Outstanding Service Award in 2008. In 2011, Mr. Lasersohn was appointed by the Office of the President to serve as an Entrepeneur in Residence at the FDA to develop an Innovation Pathway for medical devices. In 2012 he was appointed by the Secretary of HHS as a guest panel member of the Medicare Coverage and Advisory Committee (MEDCAC). He received a B.S. degree in Physics from Tufts University, an M.A. from The Fletcher School of Law and Diplomacy, and a J.D. from Yale Law School.
Erica Rogers is the President and CEO of Silk Road Medical. Prior to Silk Road Medical, Erica was the COO of Medicines360, a non-profit pharmaceutical company developing drugs and devices for women. Erica was the founder and CEO of Allux Medical, as well as the co-founder of Visiogen, which was acquired by Abbott Medical Optics in 2009. Erica spent over 12 years at Boston Scientific, in sales and marketing positions. She began her career in pharmaceutical sales after receiving a B.S. in zoology from San Diego State University. Erica holds five issued and 15 pending US patents in medical devices and nanotechnology.
Elizabeth H. Weatherman has served as a Director of Silk Road Medical since September 2011. Ms. Weatherman has held a position as Special Limited Partner of Warburg Pincus LLC, a global private equity firm focused on growth investing, since January 2016. Ms. Weatherman previously was a Managing Director of Warburg Pincus and a member of the firm’s Executive Management Group. She joined the firm Warburg Pincus in 1988 and primarily focused on the firm’s healthcare investment activities. Ms. Weatherman also serves on the board of directors of Nevro Corp., Wright Medical Group N.V. and Vapotherm, Inc. Ms. Weatherman received a B.A. summa cum laude from Mount Holyoke College and holds an M.B.A. from the Stanford Graduate School of Business.
Don Zurbay is the former vice president and CFO of St. Jude Medical, Inc., a Fortune 500 multi-national medical device company. During his tenure at St. Jude Medical, Don helped guide the company through significant growth and expansion, including nineteen acquisitions, and ultimately the transaction to sell St. Jude Medical to Abbott for $25 billion. Prior to St. Jude Medical, Inc., Don spent 10 years in public accounting at Deloitte and PricewaterhouseCoopers and three years at The Valspar Corporation. Don attended the University of Minnesota and earned a Bachelor of Science Degree in Business with an emphasis in accounting. Don is a member of the American Institute of Certified Accountants and the Minnesota Society of Certified Public Accountants. He also participated in the Advanced Management Program at Harvard Business School in 2011.